1.0Market Snapshot
- 501
- Pharmaceutical wholesalers in Switzerland in 2024 (BFS STATENT, NOGA 46.46.01). The class also counts trading and holding companies, many in Zug; a further 839 wholesalers of medical and orthopaedic products are counted separately (NOGA 46.46.02).
- 15,096
- Employees of pharmaceutical wholesalers in 2024 (BFS STATENT, NOGA 46.46.01), 13,594 full-time equivalents. The series breaks between 2022 (18,874) and 2023 (15,063); BFS gives no reason, so only 2023–2024 are compared.
- +5.0%
- Growth of the Swiss pharmaceutical market in 2025 by value (IQVIA, cited in the Galenica Annual Report 2025); volumes grew only 0.4%. Galenica's wholesale sales grew 4.8% in the same year.
According to Val Index analysis of Swiss commercial-register and federal data (2026), Switzerland counts 501 healthcare distribution companies — Pharmaceutical wholesalers in Switzerland in 2024 (BFS STATENT, NOGA 46.46.01). The class also counts trading and holding companies, many in Zug; a further 839 wholesalers of medical and orthopaedic products are counted separately (NOGA 46.46.02)..
2.0Industry Overview
Healthcare distribution moves medicines and medical products from manufacturers to pharmacies, doctors, hospitals and care homes. In 2024 BFS counted 501 pharmaceutical wholesalers with 15,096 employees (STATENT, NOGA 46.46.01), but most of that count is trading and holding companies: 90 of the units sit in Zug alone. Physical distribution is concentrated in a few full-line wholesalers. The largest, Galexis, belongs to the listed Galenica group, whose wholesale business sold CHF 3,255.3 million in 2025, up 4.8%. The Swiss pharmaceutical market grew 5.0% by value in 2025 but only 0.4% by volume (IQVIA), so growth comes from more expensive products such as biologics and GLP-1 drugs rather than more packs.
3.0Industry Health Check (SWOT)
- Stable demand from an ageing population and rising drug spending
- Very thin margins: about 2% return on sales at the market leader→ §5.0
- More cold-chain products: biologics, biosimilars and cell therapies
- Price cuts on medicines reducing the value of each delivery
Unlock full Healthcare Distribution intelligence
Market trends, cost structure, key players, succession analysis and regional clusters for Healthcare Distribution — free with Market Pulse, our monthly letter on Swiss deals.
Includes one letter a month on Swiss deals. Unsubscribe anytime.
Healthcare Distribution business valuation in Switzerland
- Statutory Multiple (EBITDA)
- 5.5 - 7.5×
- Deal Multiple (EBITDA)
- 7.0 - 10.0×
- Market Trend
- Stable
Indicative ranges based on market research. Actual multiples vary by company size, growth, and market conditions.
8.0Regional Clusters
Central Switzerland
144 pharmaceutical wholesalers with 4,440 employees in 2024 (BFS STATENT, NOGA 46.46.01); 90 of them in Zug, where many international trading companies are registered.
Western Switzerland
85 wholesalers with 2,486 employees; Galexis supplies French-speaking Switzerland from Lausanne-Ecublens, Avosano from Puidoux.
Northwestern Switzerland
69 wholesalers with 2,786 employees, close to the Basel pharmaceutical industry.
Zurich
61 wholesalers with 1,927 employees.
Ticino
61 wholesalers with 614 employees; Unione Farmaceutica Distribuzione supplies the canton.
Eastern Switzerland
42 wholesalers with 1,101 employees; Avosano (Romanshorn), Zur Rose Suisse (Frauenfeld) and Pharmapool (Widnau) are based here.
Bern and Solothurn
29 wholesalers with 1,738 employees, the highest per unit; Galexis (Niederbipp) and Alloga (Burgdorf) run their main centres here.
Sources
9.0Frequently Asked Questions
▶How much is a healthcare distribution company worth in Switzerland?
ValIndex's multiples table puts Swiss healthcare distribution at 7.0–10.0× EBITDA in transactions and 5.5–7.5× EBITDA on statutory valuations. Distributors with exclusive manufacturer contracts, Swissmedic licences and cold-chain capacity sit at the upper end; small traders dependent on one brand sit lower.
▶What drives the value of a Swiss pharmaceutical distributor?
Buyers price: (1) Swissmedic licences and GDP compliance; (2) exclusive or long contracts with manufacturers; (3) the customer base of pharmacies, doctors and hospitals; (4) cold-chain and automated warehouse capacity; (5) margin stability under medicine price cuts; (6) management and quality staff.
▶How big is Swiss pharmaceutical wholesale?
BFS counted 501 pharmaceutical wholesalers with 15,096 employees in 2024 (NOGA 46.46.01), plus 839 wholesalers of medical and orthopaedic products with 10,456 employees. The largest, Galenica, had wholesale sales of CHF 3,255.3 million in 2025.
▶Who are the main healthcare distributors in Switzerland?
Three groups lead full-line wholesale: Galenica (Galexis, Alloga, Pharmapool, Unione Farmaceutica Distribuzione), Avosano (formed in 2025 from Amedis-UE and Voigt, a Phoenix–Voigt joint venture) and Zur Rose Suisse (Medbase group).
▶What are the key trends in Swiss healthcare distribution?
Five trends: (1) the market grew 5.0% by value but 0.4% by volume in 2025; (2) Avosano was formed in January 2025; (3) cold-stored preparations rose 35% since 2020 at Galexis; (4) automation above 70% at Galexis Lausanne-Ecublens; (5) wholesalers moving into diagnostics and lab supply.
▶What are the main risks when buying a Swiss healthcare distributor?
The main risks are: (1) state price cuts on medicines; (2) loss of a manufacturer contract; (3) thin margins leaving little room for error; (4) investment needs in automation and IT; (5) competition proceedings. Due diligence should check licences, inspection reports, contract terms and customer concentration.
▶What margins do Swiss pharmaceutical wholesalers earn?
Very thin. Galenica's Logistics & IT segment, which includes Switzerland's largest wholesaler, earned an adjusted return on sales of 1.9% in 2025 (CHF 61.7 million EBIT on CHF 3,332.6 million sales), helped by one-off effects. Specialty distributors with exclusive brands earn more.
▶Where are Swiss pharmaceutical wholesalers located?
Using BFS figures for 2024: Central Switzerland has the most units (144, with 90 in Zug, many of them trading companies) and employees (4,440); Northwestern Switzerland has 2,786 employees, Western Switzerland 2,486, Zurich 1,927, Bern and Solothurn 1,738 (Galexis and Alloga), Eastern Switzerland 1,101 and Ticino 614.